TRx0237
Phase 3Small molecule
TRx0237 is one of 26 small molecule programs targeting Frontotemporal Dementia. It is currently in Phase 3.
1
Indications
6
Total Trials
0
Active Trials
25
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
38 competitors in Frontotemporal Dementia
#DrugCompanyPhaseTrials
1Namenda
AbbVieApproved
Celexa
AbbVieApproved
Gocovri
GGrupo Espanol de Tumores Neuroendocrinos
Approved
Rapamune
PPrism Pharmaceuticals
Approved
Rayos
RRoxane Laboratories
Approved
Glucophage
EMD SeronoApproved
Namenda
FForest Laboratories
Phase 3
Brintellix
TakedaPhase 2
Tasmar
BBausch Health Americas, Inc.
Phase 2
Lithobid
SSolvay Pharmaceuticals
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Alzheimer's Disease4 trials
Frontotemporal Dementia1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for TRx0237. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- TTauRx Therapeutics Ltd